Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Exclusion Criteria

• •Armpit temperature of persons with fever on the day of experimental vaccine administration\>37.0 ℃;
• •Previous history of tetanus infection;
• •Has received tetanus vaccines or vaccines containing tetanus toxoid antigen (DTP, DTP, meningococcal conjugate vaccine, etc.) within the last 10 years, or has received a tetanus immunoglobulin or tetanus antitoxin within the previous 6 months;
• •Women who are lactating, pregnant (with a positive urine pregnancy test) or planning to become pregnant within the last 3 months;
• •History of asthma, allergy to vaccines or vaccine components, and severe adverse reactions to vaccines, such as urticaria, dyspnea, angioedema, or abdominal pain;
• •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
• •Have congenital or acquired immunodeficiency such as HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA);
• •Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, asplenia or splenectomy resulting from any condition;
• •Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc;
• •Currently suffering from or have suffered from encephalopathy (such as congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection, chemical poisoning, etc.); A history of convulsions, epilepsy, psychosis or a family history of psychosis, and other serious neurological disorders;
• •Diagnosed abnormal blood coagulation function (e.g. coagulation factor deficiency, coagulation disorders, abnormal platelets) or obvious bruising or coagulation disorders;
• •Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
• •A long history of alcohol or drug abuse;
• •Receipt of blood products within in the past 3 months;
• •Receipt of attenuated live vaccines in the past 14 days;
• •Receipt of inactivated or subunit vaccines in the past 7 days;
• •Acute onset of various acute diseases or chronic diseases in the last 7 days;
• •Participating in clinical studies of other vaccines or drugs;
• •According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.